行情

UTHR

UTHR

联合治疗
NASDAQ

实时行情|Nasdaq Last Sale

185.13
+1.69
+0.92%
盘后: 185.13 0 0.00% 16:41 05/16 EDT
开盘
183.94
昨收
183.44
最高
189.87
最低
182.25
成交量
20.34万
成交额
0
52周最高
218.38
52周最低
158.38
市值
83.86亿
市盈率(TTM)
12.82
分时
5日
1月
3月
1年
5年
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Simply Wall St. · 6天前
Insider Sell: United Therapeutics
MT Newswires · 05/09 07:26
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
Zacks · 05/05 15:12
--Oppenheimer Adjusts United Therapeutics Price Target to $300 From $275, Maintains Outperform Rating
MT Newswires · 05/05 12:45
United Therapeutics reports 'best quarter' to date. Here’s what comes next.
United Therapeutics Inc. opened 2022 with a big splash in the organ transplantation arena, but it’s not the only reason Chairperson and CEO Martine Rothblatt called the first few months “the best quarter we have ever reported” for the business.
American City Business Journals · 05/04 18:38
Recap: United Therapeutics Q1 Earnings
  United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 11:47
United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 11:15
United Therapeutics Q1 EPS $5.03 Beats $3.34 Estimate, Sales $461.90M Beat $420.02M Estimate
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.03 per share which beat the analyst consensus estimate of $3.34 by 50.6 percent. This is a 44.13 percent increase over earnings of $3.49 per share from
Benzinga · 05/04 10:11
更多
暂无数据
了解UTHR最新的财务预测,通过UTHR每股收益,每股净资产,每股现金流等数据分析联合治疗近期的经营情况,然后做出明智的投资选择。
分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

45.45%强力推荐
36.36%买入
9.09%中性
9.09%落后大盘
0.00%卖出
目标价格预测
分析师预测UTHR价格均价为227.63,最高价位300.00,最低价为140.00。
最高300.00
均价227.63
最低140.00
现价185.13
EPS
实际EPS
预期EPS
1.262.523.775.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 608
机构持股: 4,744.30万
持股比例: 104.73%
总股本: 4,529.95万
类型机构数股数
增持
137
363.02万
建仓
53
107.73万
减持
159
491.15万
平仓
55
66.19万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.23%
制药与医学研究
+1.02%
高管信息
Chairman/Chief Executive Officer/Director
Martine Rothblatt
President/Chief Operating Officer
Michael Benkowitz
Non-Executive Vice Chairman/Lead Director/Independent Director
Christopher Patusky
Chief Financial Officer/Treasurer
James Edgemond
Executive Vice President/General Counsel/Secretary
Paul Mahon
Independent Director
Christopher Causey
Independent Director
Raymond Dwek
Independent Director
Richard Giltner
Independent Director
Katherine Klein
Independent Director
Raymond Kurzweil
Independent Director
Linda Maxwell
Independent Director
Nilda Mesa
Independent Director
Judy Olian
Independent Director
Louis Sullivan
Independent Director
Thomas Thompson
暂无数据
暂无数据
UTHR 简况
United Therapeutics Corp是一家生物技术公司。该公司专注于产品的开发和商业化,以满足慢性病和危及生命的疾病患者未满足的医疗需求。该公司在美国营销和销售四种治疗肺动脉高压(PAH)的商业疗法:Remodulin(曲前列环素)注射液、包括Tyvaso吸入系统的Tyvaso(曲前列环素)吸入溶液、Orenitram(曲前列环素)缓释片和Adcirca(他达拉非)片剂。该公司还在美国营销和销售肿瘤产品Unituxin(dinutuximab)注射液,该注射液被批准用于治疗高危神经母细胞瘤,以及Remodulin的Remunity Pump。该公司还从事再生医学、异种移植、离体肺灌注等多项器官移植相关技术的早期研发。

微牛提供United Therapeutics Corporation(NASDAQ-UTHR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的UTHR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易UTHR股票基本功能。